These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9777746)

  • 1. Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro-deoxyglucose positron emission tomography.
    Boerner AR; Voth E; Theissen P; Wienhard K; Wagner R; Schicha H
    Thyroid; 1998 Sep; 8(9):765-72. PubMed ID: 9777746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [F-qi-FDG PET of the thyroid gland in Graves' disease].
    Börner AR; Voth E; Wienhard K; Wagner R; Schicha H
    Nuklearmedizin; 1998; 37(7):227-33. PubMed ID: 9830612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose metabolism of the thyroid in autonomous goiter measured by F-18-FDG-PE.
    Boerner AR; Voth E; Theissen P; Wienhard K; Wagner R; Schicha H
    Exp Clin Endocrinol Diabetes; 2000; 108(3):191-6. PubMed ID: 10926315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated 18F-FDG uptake in skeletal muscles and thymus: a clue for the diagnosis of Graves' disease.
    Chen YK; Chen YL; Liao AC; Shen YY; Kao CH
    Nucl Med Commun; 2004 Feb; 25(2):115-21. PubMed ID: 15154698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orbital flourine-18-fluorodeoxyglucose positron emission tomography in patients with Graves' disease for evaluation of active inflammation.
    Uslu-Beşli L; Kabasakal L; Sağer S; Cicik E; Asa S; Sönmezoğlu K
    Nucl Med Commun; 2017 Nov; 38(11):964-970. PubMed ID: 28863123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
    Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
    J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].
    Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T
    Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves' disease.
    Dunkelmann S; Kuenstner H; Nabavi E; Rohde B; Groth P; Schuemichen C
    Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):228-36. PubMed ID: 17021811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of FDG uptake in bilateral thyroid glands.
    Chen YK; Chen YL; Cheng RH; Yeh CL; Lee CC; Hsu CH
    Nucl Med Commun; 2007 Feb; 28(2):117-22. PubMed ID: 17198352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
    Urbannek V; Voth E; Moka D; Schicha H
    Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [F-18-FDG PET in autonomous goiter].
    Börner AR; Voth E; Wienhard K; Wagner R; Schicha H
    Nuklearmedizin; 1999; 38(1):1-6. PubMed ID: 9987775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease.
    van Isselt JW; Broekhuizen-de Gast HS
    Hell J Nucl Med; 2010; 13(1):2-5. PubMed ID: 20411161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose.
    Haase A; Bähre M; Lauer I; Meller B; Richter E
    Exp Clin Endocrinol Diabetes; 2000; 108(2):133-7. PubMed ID: 10826521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioactive iodine ablation therapy: a viable option in the management of Graves' disease in Nigeria.
    Adedapo KS; Fadiji IO; Orunmuyi AT; Onimode Y; Osifo BO
    Afr J Med Med Sci; 2012 Dec; 41 Suppl():193-6. PubMed ID: 23678656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic trinity: Graves' disease on F-18 FDG PET.
    Chen YK; Wang YF; Chiu JS
    Clin Nucl Med; 2007 Oct; 32(10):816-7. PubMed ID: 17885368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
    Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
    Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.